{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    18,
    19,
    23,
    25,
    29,
    30,
    31,
    32,
    33
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "DSMB Details Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.9",
        "sectionTitle": "Data Safety Monitoring Board",
        "description": "Reference for further details on DSMB charter and meetings"
      },
      {
        "id": "ref_2",
        "name": "Study Requirements Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "STUDY PROCEDURES",
        "description": "Reference for study requirements and procedures assigned to each arm"
      },
      {
        "id": "ref_3",
        "name": "Eligibility Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5",
        "sectionTitle": "SUBJECT ELIGIBILITY",
        "description": "Reference for the complete list of inclusion and exclusion criteria"
      },
      {
        "id": "ref_4",
        "name": "Country Requirements Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix D",
        "sectionTitle": "Country-specific Requirements",
        "description": "Reference for requirements specific to country regulatory agencies"
      },
      {
        "id": "ref_5",
        "name": "Statistical Methods Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10",
        "sectionTitle": "STATISTICAL CONSIDERATIONS",
        "description": "Reference for full description of statistical analysis methods"
      },
      {
        "id": "ref_6",
        "name": "Bridging Therapy Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.2.4.2",
        "sectionTitle": "Bridging Therapy",
        "description": "Reference for details on corticosteroid bridging therapy"
      },
      {
        "id": "ref_7",
        "name": "Long-term Follow-up Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.5",
        "sectionTitle": "Duration of Study and Subject Participation",
        "description": "Reference for 15-year follow-up assessments in a separate study"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Bridging therapy: At the discretion of the investigator, corticosteroid bridging therapy may be considered for subjects with high disease burden at screening.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "STUDY SCHEMA",
        "pageNumber": 8
      },
      {
        "id": "annot_2",
        "text": "Disease Assessments: Calculated from the day of randomization and not the date of dosing with axicabtagene ciloleucel or SOC therapy.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "STUDY SCHEMA",
        "pageNumber": 8
      },
      {
        "id": "annot_3",
        "text": "After completing at least 60 months of assessments in Study KTE-C19-107, subjects who received at least one dose of axicabtagene ciloleucel as protocol therapy will complete the remainder of the 15-year follow-up assessments in a separate LTFU study.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "STUDY SCHEMA",
        "pageNumber": 8
      },
      {
        "id": "annot_4",
        "text": "Minimum observation period: 7 days unless otherwise required by country regulatory agencies (refer to Appendix D).",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "STUDY SCHEMA",
        "pageNumber": 8
      },
      {
        "id": "annot_5",
        "text": "This document contains confidential information of Kite Pharma, Inc. This document must not be disclosed to anyone other than the study site research staff, collaborators, and members of the IRB/IEC.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "CONFIDENTIALITY STATEMENT",
        "pageNumber": 1
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "1.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-05-22",
        "description": "Original Protocol",
        "amendmentNumber": "Original"
      },
      {
        "id": "ver_2",
        "versionNumber": "2.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-09-27",
        "description": "Version 2",
        "amendmentNumber": "Amendment 1"
      },
      {
        "id": "ver_3",
        "versionNumber": "3.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-11-21",
        "description": "Protocol Amendment 2",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_4",
        "versionNumber": "4.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-01-16",
        "description": "Protocol Amendment 3",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_5",
        "versionNumber": "5.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-03-19",
        "description": "Protocol Amendment 4",
        "amendmentNumber": "Amendment 4"
      },
      {
        "id": "ver_6",
        "versionNumber": "6.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-06-25",
        "description": "Protocol Amendment 5",
        "amendmentNumber": "Amendment 5"
      },
      {
        "id": "ver_7",
        "versionNumber": "6.1",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-09-16",
        "description": "USA only",
        "amendmentNumber": "Amendment 5.1"
      },
      {
        "id": "ver_8",
        "versionNumber": "7.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2023-04-14",
        "description": "Current version of the document",
        "amendmentNumber": "Amendment 6"
      }
    ],
    "summary": {
      "referenceCount": 7,
      "annotationCount": 5,
      "versionCount": 8
    }
  }
}